Literature DB >> 7104515

A study of the inhibitory effects of SCH 28080 on gastric secretion in man.

M D Ene, T Khan-Daneshmend, C J Roberts.   

Abstract

1 SCH 28080 (2-methyl-8-(phenyl methoxy) imidazo-(1-2-a) pyrine-3-acetonitrile) is a novel drug unrelated to existing anti-ulcer agents. 2 The effect of placebo and increasing doses of the drug on gastric acid output and peptic activity was examined in four healthy men, in the resting state and following pentagastrin stimulation. 3 Significant inhibition of gastric acid secretion and peptic activity occurred with the 50 mg dose in both the stimulated and unstimulated states. Approximately 90% inhibition of acid output was achieved with the 200 mg dose. 4 Antisecretory activity of SCH 28080 is confirmed in man. This drug or an analogue may have potential in anti-ulcer therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104515      PMCID: PMC2071808          DOI: 10.1111/j.1476-5381.1982.tb09232.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  4 in total

1.  Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins.

Authors:  A Robert
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1976

2.  A modified hemoglobin substrate method for the estimation of pepsin in gastric juice.

Authors:  A Berstad
Journal:  Scand J Gastroenterol       Date:  1970       Impact factor: 2.423

3.  The effect of ranitidine and cimetidine on pentagastrin and insulin stimulated gastric secretion.

Authors:  R Sheers; N Roberts
Journal:  Scand J Gastroenterol Suppl       Date:  1981-06

4.  Cerebral blood-flow in polycythaemia.

Authors:  D J Thomas; G H du Boulay; J Marshall; T C Pearson; R W Ross Russell; L Symon; G Wetherley-Mein; E Zilkha
Journal:  Lancet       Date:  1977-07-23       Impact factor: 79.321

  4 in total
  8 in total

Review 1.  Role of potassium in acid secretion.

Authors:  John-P Geibel
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

2.  The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.

Authors:  D R Scott; K B Munson; E A Marcus; N W G Lambrecht; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2015-09-30       Impact factor: 8.171

3.  Effects of SCH 32651 on resting and stimulated acid secretion in guinea-pig isolated fundic mucosa.

Authors:  A Barnett; P J Chiu; G Tetzloff
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

Review 4.  Pharmacological aspects of acid secretion.

Authors:  B I Hirschowitz; D Keeling; M Lewin; S Okabe; M Parsons; K Sewing; B Wallmark; G Sachs
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 5.  Potassium Channelopathies and Gastrointestinal Ulceration.

Authors:  Jaeyong Han; Seung Hun Lee; Gerhard Giebisch; Tong Wang
Journal:  Gut Liver       Date:  2016-11-15       Impact factor: 4.519

Review 6.  Potassium-competitive acid blockers and gastroesophageal reflux disease.

Authors:  Wattana Leowattana; Tawithep Leowattana
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

Review 7.  The role of vonoprazan in patients with erosive esophagitis.

Authors:  Mengyu Zhang; Yinglian Xiao; Minhu Chen
Journal:  Therap Adv Gastroenterol       Date:  2022-09-13       Impact factor: 4.802

Review 8.  Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.

Authors:  Kentaro Sugano
Journal:  Therap Adv Gastroenterol       Date:  2018-01-09       Impact factor: 4.409

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.